We work towards the personalization and actualization of medicines. To achieve these goals, we rely on modern techniques for collecting large amounts of biological data, and methods for analyzing data that lead to conclusions or new hypotheses. We work across scales, from single cells, to bulk cell populations, to bulk human populations, scaling rare finding into accessible medicines. 

The systems immunology team uses single cell sequencing to identify rare cell types or clonotypes from clinical samples related to several medical conditions and pathogens. From these data, we infer patient-specific mechanisms in therapeutic response, and identify new engineering targets. The biomanufacturing teams work to improve the accessibility and lower the cost of manufacturing of protein therapeutics. Alternative hosts like the yeast Pichia pastoris provide promise for cost effective expression of high quality human proteins. In parallel, we engineer products themselves at the sequence level to "fit" the manufacturing host and improve product quality from the point of design. Finally, we use our benchtop scale, perfusion bioreactor system to perform rapid, at-scale process development. These new approaches could improve how and where medicines are produced for patients, and ultimately their accessibility globally. 


Systems Immunology

Single cell resolution of T-cell and B-cell receptors is changing how we can characterize human disease. more >>


Protein biopharmaceuticals

Only small regions of proteins carry out medicinal functions, the rest can be designed for manufacturability. more >>


Integrated process development

Using biology to inform upstream and downstream process development enables benchtop scale manufacturing. more >>


Alternative host strain engineering

Single celled eukaryotes have all the capabilities of mammalian cells without any of the baggage. more >>